Molecular Partners AG is a clinical-stage biotechnology company developing protein-based therapeutics for oncology applications. The company specializes in designed ankyrin repeat proteins, known as DARPins, which serve as the foundation for its drug candidates. Its pipeline includes MP0317, a tetra-specific T cell-engaging therapy in Phase 1 trials for advanced solid tumors, and MP053, also in Phase 1 development for acute myeloid leukemia. The company is advancing MP0712, a radio-labeled DARPin therapy targeting delta-like ligand 3, in preclinical development for small cell lung cancer and neuroendocrine tumors.
Molecular Partners is developing two primary therapeutic platforms: Switch-DARPin T cell engagers designed to enhance immune cell targeting and killing capacity, and Radio-DARPin Therapy, which delivers radioactive payloads to solid tumors. The company also has early-stage programs in HSC conditioning and ovarian disease indications. Earlier-stage programs remain in preclinical phases.
The company operates through strategic collaborations with specialized partners. It has agreements with Orano Med SAS and Eckert & Ziegler SE for the development and optimization of its Radio-DARPin therapeutic candidates. Headquartered in Schlieren, Switzerland, Molecular Partners employs 158 full-time staff and is listed on Nasdaq. The company was incorporated in 2004.
No 10-K filings found.